Guggenheim Maintains Neutral on Amgen, Raises Price Target to $388

Benzinga Newsdesk www.benzinga.com Positive 60.5%

Neg 0% Neu 0% Pos 60.5%

Guggenheim analyst Vamil Divan maintains Amgen (NASDAQ:AMGN) with a Neutral and raises the price target from $343 to $388.